💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
FDC Limited is an India-based company, which is principally engaged in the business of manufacturing and trading of pharmaceutical products. The Company is specialized in manufacturing Oral Rehydration Solutions (ORS), energy drinks, antibiotics and ophthalmic therapies. Its…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, steadily growing business, reasonably priced.
FDC Limited is scored on the pharma / healthcare framework. It keeps a healthy 12.3% of every rupee of sales as net profit. Cash conversion lags the reported profit (CFO/PAT 0.71×) — worth a closer look. Free cash flow is worth about 1.4% of its market value.
Over the last 3 years revenue compounded at 8%/yr and profit at 13%/yr. Book value has grown 8%/yr. Return on equity is a modest 11.7%. In the latest quarter profit fell 63% versus the prior quarter.
At 23× earnings, the stock sits at the 21st percentile of its own 3.6-year range — the cheap end of where it has historically traded. Today's price implies ~9%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 20.27 | — | — |
| P/B | 2.38 | 4.1 | better |
| EV/EBITDA | 13.16 | 19.33 | better |
| ROE | 11.74 | — | — |
| ROCE | 15.71 | 14.41 | better |
| ROA | 9.86 | — | — |
| Quick Ratio | 2.13 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 8% CAGR — growing but slowly.
Profit is growing faster than revenue (13% vs 8%) — margin expansion is at work.
Operating margin has expanded from 14% to 16% — the business is keeping more of each rupee earned.
ROE at 11% — modest; the capital isn't working hard. Low variance across years — a predictable business that earns steadily on its equity base.
14% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue fell 18% QoQ — could be seasonality or a genuine slowdown. Wide quarterly swings (32% spread) — likely seasonality, lumpy orders, or project-based revenue. Run-rate stepping up — recent quarters average 17% above earlier ones.
Profit fell 63% QoQ — one-quarter drops can be noise, but a pattern matters. Quarterly net margins are expanding (6% → 8%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters hold 69.7% — heavily owner-operated with strong skin in the game.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.